Product Search
If you experience any issues, try switching to another browser such as Chrome, or to another device such as phone or laptop, to complete your order.
Product Search

Secure Checkout
Multiple Myeloma Health Topic
    Multiple Myeloma Health Topic
    Questions?  1 (951) 639-9708

    Multiple Myeloma Health Topic

    Multiple myeloma news and research. Myeloma is a haematological malignancy which typically follows a relapsing-remitting course. While treatment can control the myeloma and improve quality of life for given periods of time, remissions generally become progressively shorter with subsequent relapses, and patients ultimately enter a final refractory phase. To help control symptoms and enhance quality of life, some patients use complementary therapies as an adjunct to their conventional therapy.1

    Learn More About Multiple Myeloma Research

    1. Long-Term Stabilisation of Myeloma with Curcumin

      Here, we describe a myeloma patient who started a daily dietary supplement of curcumin when approaching her third relapse. In the absence of further anti-myeloma treatment, the patient plateaued and has remained stable for the last 5 years with good quality of life.


    2. Long-Term Follow-Up of Curcumin Treated MGUS/SMM Patients – An Updated Single Centre Experience

      Our data suggest that curcumin administration may benefit some patients diagnosed with MGUS or SMM with little or no toxicity even after 9 years of therapy. Future studies should assess the role of curcumin in both MGUS and SMM patients – prior to progression to high risk or active myeloma – as this may lead to a delay in or may even stop disease progression.


    3. Celyad's Trial Evaluating CAR T-Cells in 7 Cances to Start Enrolling Patients in the US

      CAR T-cells are a type of engineered immune cells that have shown tremendously good results in studies. While most CAR T-cell therapies recognize a unique cancer antigen, Celyad's NKR-2 CAR T-cells express the human receptor NKG2D, which recognizes eight naturally occurring ligands that are overexpressed in more than 80 percent of tumors. Preclinical studies have shown that NKR-2 CAR T-cells not only induce direct cancer cell death, they also destroy the tumor's blood supply, inhibit the mechanisms that enable the tumor to evade immune surveillance, and activate other anti-tumor immune cells.

    4. A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)

      Information about an immunotherapy clinical trial signing up patients in the US and Belgium.


    5. CAR T Cells: Expanding into Multiple Myeloma

      A form of immunotherapy that uses genetically engineered immune cells may be highly effective in patients with advanced multiple myeloma. CAR T cells use a patient's own immune cells to treat their disease and are still largely in the clinical development phase. In this form of therapy, immune cells are collected from a patient's blood; engineered in the laboratory to produce special receptors called chimeric-antigen receptors, or CARs, that attach to a specific target on cancer cells (an antigen); grown in the lab until they number in the billions; and then reinfused back into the patient.

    6. CAR-T Cancer Approach Has Surprising Success in Multiple Myeloma

      Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that's on the rise. Although it's early and the study is small – 35 people – every patient responded and all but two were in some level of remission within two months. The treatment, called CAR-T therapy, involves filtering a patient's blood to remove immune system soldiers called T cells. These are altered in a lab to contain a gene that targets cancer and then given back to the patient intravenously.

    7. Turmeric Curcumin and Its Affect on Multiple Myeloma

      In the video on this page, you can see the unimpeded growth of four different cell lines of multiple myeloma. We start out with about 5,000 cancer cells at the beginning of the week, which then doubles, triples and quadruples in a matter of days. If we add a little bit of curcumin, growth is stunted. If we add a lot of curcumin, growth is stopped. About 1 in 3 of the patients responded to the curcumin with dropping paraprotein levels, whereas there were no responses in the placebo group. These positive findings prompted researchers to commence a double-blind, randomized, controlled trial.


    8. New Recipe To Treat Multiple Myeloma? Scientists Combine Turmeric Spice With Thalidomide

      Overall, the combination of the spice and the drug was significantly more potent than either individually, suggesting that this hybrid strategy in drug design could lead to novel compounds with improved biological activities. In their study, the researchers created more than 15 compounds from the hybrid molecules of turmeric and thalidomide, with each creating a different effect.

    9. Omega-3 Fatty Acids, EPA and DHA Induce Apoptosis and Enhance Drug Sensitivity in Multiple Myeloma Cells

      Study suggests that the 0mega-3 fatty acids EPA and DHA induce selective cytotoxic effects in Multiple Myeloma and enhance the effect of chemotherapeutic drug bortezomib.


    Tags: multiple myeloma, smoldering multiple myeloma, MGUS, SMM, multiple myeloma and curcumin, multiple myeloma and CAR T-cells, multiple myeloma and turmeric

    Statements on this website have NOT been evaluated by the Food and Drug Administration and are NOT intended to diagnose, treat, cure, or prevent any disease; research is ongoing. All third-party health topic links provided on this website are for information purposes only. Always consult your doctor or nutritionist about any health or nutrition-related questions you might have.